Antiphospholipid syndrome in renal transplantation

Nephrology (Carlton). 2014 Apr;19(4):177-85. doi: 10.1111/nep.12217.

Abstract

Antiphospholipid syndrome (APS) may occur in isolation or in association with systemic lupus erythematosus (SLE), with the potential to cause renal failure via several distinct pathologies. Renal transplantation in the presence of APS carries a risk of early graft loss from arterial or venous thrombosis, or thrombotic microangiopathy (TMA). Whilst perioperative anticoagulation reduces the risk of large vessel thrombosis, it may result in significant haemorrhage, and its efficacy in preventing post-transplant TMA is uncertain. Here, we report a patient with end-stage kidney disease (ESKD) due to lupus nephritis and APS, in whom allograft TMA developed soon after transplantation despite partial anticoagulation. TMA resolved with plasma exchange-based therapy albeit with some irreversible graft damage and renal impairment. We discuss the differential diagnosis of post-transplant TMA, and current treatment options.

Keywords: antiphospholipid; lupus; plasma exchange; thrombotic microangiopathy.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome / complications*
  • Antiphospholipid Syndrome / diagnosis
  • Antiphospholipid Syndrome / drug therapy
  • Biopsy
  • Diagnosis, Differential
  • Humans
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation / adverse effects*
  • Lupus Nephritis / complications*
  • Lupus Nephritis / diagnosis
  • Male
  • Plasma Exchange
  • Predictive Value of Tests
  • Thrombotic Microangiopathies / diagnosis
  • Thrombotic Microangiopathies / etiology*
  • Thrombotic Microangiopathies / therapy
  • Treatment Outcome

Substances

  • Anticoagulants